EyePoint Pharmaceuticals (NASDAQ:EYPT) reported quarterly losses of $(0.85) per share which missed the analyst consensus estimate of $(0.79) by 7.87 percent. This is a 57.41 percent decrease over losses of $(0.54) per share from the same period last year. The company reported quarterly sales of $966.000 thousand which missed the analyst consensus estimate of $3.329 million by 70.99 percent. This is a 90.82 percent decrease over sales of $10.524 million the same period last year.